Jounce Therapeutics (NASDAQ:JNCE) Earns Sell Rating from JPMorgan Chase & Co.
JNCE stock opened at $4.25 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.03 and a debt-to-equity ratio of 0.20. Jounce Therapeutics has a 52-week low of $2.66 and a 52-week high of $8.58. The business’s 50 day simple moving average is $4.45. The stock has a market cap of $138.52 million, a P/E ratio of -5.06 and a beta of 3.44.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. Jounce Therapeutics had a negative return on equity of 29.64% and a negative net margin of 46.07%. The company had revenue of $17.45 million for the quarter, compared to the consensus estimate of $17.09 million. Equities research analysts anticipate that Jounce Therapeutics will post 0.72 EPS for the current fiscal year.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Featured Story: How to start trading in the forex market?
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.